Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival

Essam Ghazaly(Queen Mary University of London), Sarah P. Blagden(Churchill Hospital), Magdalena Ślusarczyk(Cardiff University), David J. Harrison(NHS Lothian), Christopher McGuigan(University College Dublin)

Molecular Cancer Therapeutics

December 1, 2015

10.1158/1535-7163.targ-15-b46

Cited by 9

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

|eLife|2017|201

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

|Clinical Cancer Research|2011|168